CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
11. November 2024 07:30 ET
|
CytoSorbents; Converge Biotech
CytoSorbents and Converge Biotech Partner In India to Expand CytoSorb Blood Purification Availability to Treat Sepsis and Other Deadly Conditions
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07. November 2024 16:05 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22. Oktober 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
17. Oktober 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Announce Q3 2024 Financial and Operating Results on November 7, 2024
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
27. August 2024 07:00 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
13. August 2024 16:19 ET
|
CytoSorbents
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by...
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
13. August 2024 16:18 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
07. August 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
01. August 2024 07:00 ET
|
CytoSorbents
CytoSorbents regains compliance with Nasdaq minimum bid price requirement
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
30. Juli 2024 02:00 ET
|
CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"